

Environmental and Social Data Sheet

Overview

Project Name: *GREENBONE (EGF VD)*
Project Number: *2021-0382*
Country: *Italy*
Project Description: *Quasi-equity loan to Greenbone. Italian medtech working on bone replacement solutions.*

EIA required: no

Project included in Carbon Footprint Exercise¹: no

Environmental and Social Assessment

Environmental Assessment

The project's activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU. The project's RDI activities are a central part of the promoter's operations and will be embedded in the existing organisational and management structure. The project will not result in residual environmental impact as it will be carried out in existing and authorised research facilities. The promoter's practices are in compliance with the relevant national and EU regulations for medical devices (Regulation (EU) 2017/745 on medical devices (MDR), Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) (1990), and Council Directive 93/42/EEC on Medical Devices (MDD) (1993)), as well as regulations for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products (e.g. directives 2001/83/EC, 2005/28/EC, 2001/20/EC and applicable good practice quality guidelines and regulations).

Social Assessment, where applicable

- Gender equality

The project will generate positions accessible to highly qualified RDI workers in Faenza, Italy, which would provide increased access to social and economic benefits. The promoter is an equal opportunity employer, committed to gender equality, with an active program for promoting women in science.

Other Environmental and Social Aspects

Through the RDI activities and investments, the promoter expects to increase its current

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, 15.12.21

level of highly skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

The promoter is committed to animal welfare and the responsible use of animals for scientific purposes. Moreover, the promoter complies with the European Directive 2010/63/EU on the protection of animals used for scientific purposes, where applicable.

Conclusions and Recommendations

The project concerns investments in research and development in human health products that will be carried out in existing facilities. The project's activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU..The research activities undertaken in the project are aimed at delivering novel and improved medicinal products with a positive impact on healthcare. Therefore, the project, if successful, is expected to bring positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects